Tollovir™: 3CL Protease Inhibitor

A highly potent 3CL protease inhibitor as a COVID-19 pharmaceutical

Phase 2 Clinical Stage 3CL Protease Inhibitor for Hospitalized Patients

Todos is developing a more concentrated version of Tollovid using a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses. Todos is currently supporting randomized, placebo-controlled clinical trials managed by JV partner NLC Pharma in Israel. Tollovir is the result of over 15 years of development and an investment of over $18M to date.


Scientifically Studied


Vegan Friendly


Traceable Ingredients 

Learn More About This Clinical-Stage 3CL Protease Inhibitor

How Protease Inhibitors Can Be the Key to Fighting COVID-19

COVID-19, like any other virus, is a single strand of RNA (or DNA) that spreads with a simple two-step process:

I. Break into a healthy cell

II. Hijack the cell’s own mechanisms to make copies of itself

Studies have shown, however, that by using protease inhibitors, we can stop the virus’ ability to replicate itself, halting the spread in it tracks. To understand how this is done, let’s take a closer look at the lifecycle of a virus:


First, the virus must get inside the cell. Every virus does this slightly differently, but Coronaviruses (such as COVID-19) use their signature “spikes” to fuse themselves to a cell’s outer wall and then squeeze their way inside. A virus is a single strand of RNA wrapped in a protein envelope. The RNA contains the genetic instructions the virus needs to make copies of itself.




Once inside, the virus RNA converts into a polypeptide. This long protein is like a bus for the team of enzymes whose job it is to make more of the virus.When the virus invades a human cell, its’ RNA is translated into a polypeptide, a long protein chain that includes several enzymes necessary to continue replication.


Before these enzymes can start working, they need to be separated from each other. The protease enzyme acts like a pair of scissors, cutting the polypeptide up into the different enzymes, that then become functional.



By using a protease inhibitor, the protease enzyme is blocked from doing this. These drugs are designed to tightly bind to the protease enzyme, blocking its ability to cut. This leaves the entire virus-making team stuck on their bus, without being able to make a single virus. Sad for the virus, happy for the host.

Want to learn more?

Stay in the loop. Subscribe to our emails.